MH
MEIRAGTX HOLDINGS PLC
StreetZero Signal 60
About MEIRAGTX HOLDINGS PLC
MeiraGTx Holdings plc (Nasdaq: MGTX) is a vertically integrated, clinical stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. Led by an experienced management team, MeiraGTx has taken a portfolio approach by licensing, acquiring and developing technologies.
LATEST FUNDINGRule 144
$557K
Announced 2026-10-20
IN THE NEWS
- 🔗 MeiraGTx Holdings plc (Nasdaq
- 🔗 MeiraGTx Holdings plc (NASDAQ:MGTX) stock most popular amongst private equity firms who own 28%, while individual investors hold 26%
- 🔗 MeiraGTx Holdings plc (NASDAQ:MGTX) has caught the attention of institutional investors who hold a sizeable 31% stake
- 🔗 Hedge Funds Aren’t Crazy About MeiraGTx Holdings plc (MGTX) Anymore
- 🔗 MeiraGTx Holdings PLC Reports Notable Clinical Progress Amidst Financial Challenges in 2023
EMPLOYEES393
FOUNDED—
HQNEW YORK, NY
Industry
Public Equity (NASDAQ)
Tags
Gene TherapyBiotechnologyClinical StageNASDAQ
Key highlights
- MeiraGTx reported cash and equivalents of approximately $199.4 million as of March 31, 2021 plus $12 million in Janssen receivables.
- CEO Alexandria Forbes directly holds between 1.6% and 2.2% of shares.
- The company forecasts operations funded into Q1 2026 excluding potential $285 million Janssen milestones.
- Institutional investors hold 31% of shares with hedge funds at 15%.
Ask StreetZero about MEIRAGTX HOLDINGS PLC
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account